Aug 4, 2026 03:05AM

Jul 31, 2026 06:25PM

Jun 23, 2026 05:20PM

Jun 23, 2026 05:20PM

Jun 15, 2026 03:45AM

Jun 10, 2026 06:30PM

May 19, 2026 03:05AM BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

Apr 28, 2026 03:05AM

Apr 14, 2026 03:05AM

Apr 7, 2026 03:05AM

Mar 30, 2026 03:05AM

Mar 24, 2026 05:10AM

Mar 17, 2026 03:05AM

Mar 17, 2026 03:05AM BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

Feb 26, 2026 07:00PM

Feb 17, 2026 03:05AM

Feb 5, 2026 03:05AM

Jan 26, 2026 03:05AM

Jan 21, 2026 03:05AM

Jan 19, 2026 03:05AM

Dec 17, 2025 03:05AM Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies

Dec 9, 2025 03:05AM

Dec 1, 2025 03:05AM

Dec 1, 2025 03:05AM

Nov 20, 2025 03:05AM

Nov 4, 2025 03:05AM

Oct 30, 2025 03:05AM

Oct 21, 2025 03:05AM BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study

Oct 9, 2025 07:50PM

Oct 9, 2025 03:05AM

Oct 2, 2025 03:05AM

Sep 29, 2025 03:05AM

Sep 19, 2025 07:30PM

Sep 12, 2025 07:00PM

Sep 5, 2025 03:05AM BioNxt Solutions Completes Up-Listing to The OTCQB Market

Aug 15, 2024 03:05AM

Jul 17, 2024 03:05AM

Jul 9, 2024 03:05AM

443,903 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All